Consenso Colombiano en Hipertensión Arterial Pulmonar Recomendaciones basadas en consenso de expertos e informadas en la evidencia para el diagnóstico, tratamiento y seguimiento en hipertensión pulmonar.

Colombian Consensus on Pulmonary Arterial Hypertension. Recommendations based on expert consensus and informed by evidence for the diagnosis, treatment, and follow-up of pulmonary hypertension.

Publicado 2025-01-10

Abrir | Descargar
PDF FLIP
Número
Vol. 36 Núm. 2Supl-1 (2024): Suplemento
Sección
Consensos y guias
Cómo citar
Pacheco Gallego MC, Rodríguez Cortes CA, Contreras Páez RD, Fernández Trujillo L, Blanco Mosquera JL, Campo Campo FDJ, et al. Consenso Colombiano en Hipertensión Arterial Pulmonar Recomendaciones basadas en consenso de expertos e informadas en la evidencia para el diagnóstico, tratamiento y seguimiento en hipertensión pulmonar.
rev. colomb. neumol. [Internet]. 2025 Jan. 10 [cited 2025 May 31];36(2Supl-1):1-102. Disponible en: https://doi.org/10.30789/rcneumologia.v36.n2Supl-1.2024.1029
DOI

https://doi.org/10.30789/rcneumologia.v36.n2Supl-1.2024.1029
Dimensions
PlumX
Licencia
Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Manuel Conrado Pacheco Gallego
Clínica San Rafael
Roles:  
https://orcid.org/0000-0001-6783-1608
Camilo Andrés Rodríguez Cortes
Instituto de Cardiología image/svg+xml
Roles:  
Rubén Darío Contreras Páez
Clínica Reina Sofía Pediátrica y Mujer
Roles:  
https://orcid.org/0000-0001-6808-3306
Liliana Fernández Trujillo
Fundación Valle del Lili image/svg+xml
Roles:  
https://orcid.org/0000-0003-0789-9154
José Luis Blanco Mosquera
Clínica Comfamiliar
Roles:  
https://orcid.org/0000-0003-2861-7005
Mostrar biografía de los autores

Manuel Conrado Pacheco Gallego,

Especialista en Neumología. Respiremos SAS, Clínica Comfamiliar, Clínica San Rafael

Liliana Fernández Trujillo ,

Especialista en Neumología. 

José Luis Blanco Mosquera ,

  Especialista en Neumología

Felipe De Jesús Campo Campo,

Subespecialista de neumología intervencionista. 

Iván De Jesús Baños Álvarez ,

Especialista en Neumología

John Alexander Ramírez Martínez ,

Especialista en Medicina Interna y Cardiología

Cesar Enrique Cuellar Cortés ,

Cardiólogo Intervencionista 

José Federico Saaibi Solano ,

Especialista en Medicina Interna y Cardiología

Lina María Saldarriaga Rivera ,

Especialista en Reumatología 

Diana Rocío Gil Calderón ,

Especialista en Reumatología

Andrés Chavarriaga Restrepo ,

Especialista en Reumatología

Claudio Villaquirán Torres ,

Especialista en Neumología

José Rubén Dueñas Villamil ,

Especialista en Neumología

Diana Patricia Ortiz Barajas ,

Especialista en Neumología

Ingrid Johana Martínez Ramírez ,

Especialista en Neumología

Mauricio Ariel Orozco Levi ,

Especialista en Neumología

Juan Pablo Camargo Mendoza ,

Especialista en Neumología

Rafael Enrique Conde Camacho ,

Especialista en Neumología

Jaime Alberto Rodríguez ,

Especialista en Cardiología

Efraín Gómez ,

Especialista en Cardiología

Ricardo Gómez Palau ,

Especialista en Cardiología

Juan Esteban Gómez ,

Especialista en Cardiología

Jorge Luis Quintero Barrios ,

Especialista en Neumología

Alba Ramírez Sarmiento ,

Doctorado en Ciencias de la Salud y de la Vida

Vinicio de Jesús Pérez ,

Especialista en Neumología 

Juan Pablo Zuluaga Peña,

Máster en Administración de Empresas

Lucila Teresa Flórez De Arco ,

Especialista en Neumología

Manuela Tobón Trujillo ,

Especialista en Neumología

Alejandro Londoño Villegas ,

Especialista en Neumología

Julia Edith Chamorro Ortega ,

Especialista en Neumología

Juan Fernando Carvajal ,

Especialista en Cardiología

Luis Eduardo Echeverría ,

Especialista en Cardiología

Angelo Valencia ,

Especialista en Cardiología Pediátrica 

Julio Ricardo Zuluaga Peña,

Magíster en Economía de la Salud

Isabel Cristina Casas Quiroga,

Magíster en Epidemiología

Introducción: la hipertensión arterial pulmonar (HAP) es una condición clínica caracterizada por la disfunción del endotelio arterial pulmonar que se manifiesta con un aumento en la restricción del flujo en la circulación pulmonar. Se han realizado numerosos avances en la comprensión de la fisiopatología, la estratificación del riesgo, el tratamiento y el seguimiento de los pacientes con esta enfermedad. Entre estos avances se encuentra la actualización en la definición hemodinámica del evento, lo que determina en gran medida las acciones terapéuticas a seguir. Por lo anterior, se consideró necesario establecer las recomendaciones para el manejo de los pacientes con HAP, a partir de un enfoque que considere los aspectos propios del acceso, uso y prestación de los servicios en Colombia. 

Metodología: la construcción del documento final se desarrolló en seis etapas: 1. Definición de las preguntas de investigación y el contenido; 2. Búsqueda, tamización, selección y evaluación de la evidencia; 3. Elaboración de un resumen narrativo de la evidencia basado en las preguntas orientadoras; 4. Discusión de los hallazgos en paneles formales; 5. Formulación de recomendaciones y, 6. Redacción y consolidación del documento final de consenso.

Resultados: los 34 participantes llegaron a un consenso y formularon 26 recomendaciones a partir de cuatro segmentos temáticos: i) definiciones y diagnóstico; ii) estratificación del riesgo; iii) tratamiento y, iv) seguimiento. 

Conclusión: las recomendaciones formuladas servirán como guía para los médicos de atención primaria en la orientación de la sospecha clínica de la enfermedad y para especialistas y subespecialistas en la confirmación del diagnóstico, así como en la definición del abordaje terapéutico y el seguimiento de los pacientes. A medida que surja nueva evidencia, estas recomendaciones deberán revisarse y actualizarse cuidadosamente.

Visitas del artículo 368 | Visitas PDF 398

Descargas

Los datos de descarga todavía no están disponibles.
  1. Cullivan S, Higgins M, Gaine S. Diagnosis and management of pulmonary arterial hypertension. Breathe (Sheff). 2022;18(4):220168. doi:10.1183/20734735.0168-2022 DOI: https://doi.org/10.1183/20734735.0168-2022
  2. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1). doi:10.1183/13993003.01913-2018 DOI: https://doi.org/10.1183/13993003.01913-2018
  3. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RM, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). European Heart Journal. 2022;43(38):3618-731. DOI: https://doi.org/10.1093/eurheartj/ehac237
  4. Maron BA, Abman SH, Elliott CG, Frantz RP, Hopper RK, Horn EM, et al. Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. Am J Respir Crit Care Med. 2021;203(12):1472-87. doi:10.1164/rccm.202012-4317SO DOI: https://doi.org/10.1164/rccm.202012-4317SO
  5. Instituto de Evaluacion Tecnológica en Salud. Guía Metodológica para la elaboración de Guías de Práctica Clínica con Evaluación Económica en el Sistema General de Seguridad Social en Salud Colombiano. Bogotá D.C.: IETS; 2014.
  6. Instituto de Evaluación Tecnológica en Salud. Manual metodológico para la elaboración de evaluaciones de efectividad clínica, seguridad y validez diagnóstica de tecnologías en salud. Bogotá D.C.: IETS; 2022.
  7. Instituto de Evaluación Tecnológica en Salud. Guía Metodológica para la elaboración de Guías de Práctica Clínica en el Sistema General de Seguridad Social en Salud Colombiano. Bogotá D.C.: IETS; 2017.
  8. Ministerio de Salud y Protección Social. Guía Metodológica, Adopción Adaptación de Guías de Práctica Clínica Basadas en Evidencia. Bogotá DC: Instituto de Evaluación Tecnológica en Salud (IETS); 2017. p. 1-63; Disponible en: https://www.iets.org.co/Archivos/79/Guia_de_Adopcion_VF.pdf
  9. Consorcio AGREE C. Instrumento AGREE II. Instrumento para la evaluación de guías de práctica clínica [en línea]. Versión en español GuíaSalud; 2009.
  10. Seto K, Matsumoto K, Kitazawa T, Fujita S, Hanaoka S, Hasegawa T. Evaluation of clinical practice guidelines using the AGREE instrument: comparison between data obtained from AGREE I and AGREE II. BMC research notes. 2017;10(1):716. doi:10.1186/s13104-017-3041-7 DOI: https://doi.org/10.1186/s13104-017-3041-7
  11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed). 2021;372:n71. doi:10.1136/bmj.n71 DOI: https://doi.org/10.1136/bmj.n71
  12. Higgins JPT G. Manual Cochrane de Revisiones Sistemáticas de Intervenciones. Versión 5.1.0.2012.
  13. Urrútia G, Bonfill X. Declaración PRISMA: una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis. Medicina clínica. 2010;135(11):507-11. DOI: https://doi.org/10.1016/j.medcli.2010.01.015
  14. Whiting P, Savovic J, Higgins JP, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225-34. doi:10.1016/j.jclinepi.2015.06.005 DOI: https://doi.org/10.1016/j.jclinepi.2015.06.005
  15. D'Alto M, Motoji Y, Romeo E, Argiento P, Di Marco GM, Mattera Iacono A, et al. Fluid challenge predicts clinical worsening in pulmonary arterial hypertension. Int J Cardiol. 2018;261:167-71. doi:10.1016/j.ijcard.2018.03.020 DOI: https://doi.org/10.1016/j.ijcard.2018.03.020
  16. Qaiser KN, Almoushref A, Mehta AK, Alkhayyat M, Lane JE, Tonelli AR. Fluid loading during the hemodynamic evaluation of pulmonary hypertension: a cross-sectional study. Cardiovasc Diagn Ther. 2023;13(5):833-42. doi:10.21037/cdt-23-59 DOI: https://doi.org/10.21037/cdt-23-59
  17. Pezzuto B, Badagliacca R, Muratori M, Farina S, Bussotti M, Correale M, et al. Role of cardiopulmonary exercise test in the prediction of hemodynamic impairment in patients with pulmonary arterial hypertension. Pulm Circ. 2022;12(1):e12044. doi:10.1002/pul2.12044 DOI: https://doi.org/10.1002/pul2.12044
  18. Saunders H, Helgeson SA, Abdelrahim A, Rottman-Pietrzak K, Reams V, Zeiger TK, et al. Comparing Diagnosis and Treatment of Pulmonary Hypertension Patients at a Pulmonary Hypertension Center versus Community Centers. Diseases. 2022;10(1). doi:10.3390/diseases10010005 DOI: https://doi.org/10.3390/diseases10010005
  19. Moola S, Munn Z, Sears K, Sfetcu R, Currie M, Lisy K, et al. Conducting systematic reviews of association (etiology): The Joanna Briggs Institute's approach. Int J Evid Based Healthc. 2015;13(3):163-9. doi:10.1097/XEB.0000000000000064 DOI: https://doi.org/10.1097/XEB.0000000000000064
  20. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-731. doi:10.1093/eurheartj/ehac237 DOI: https://doi.org/10.1093/eurheartj/ehac237
  21. Conde-Camacho R, Orozco-Levi M, Londoño A, Acosta DF, Alvarado JJ, Carvajal JF, et al. Consenso de especialistas sobre la estratificación, el manejo y el seguimiento del paciente con hipertensión pulmonar del grupo 1 con riesgo intermedio. Revista Colombiana de Cardiología. 2023;30(2):95-107. DOI: https://doi.org/10.24875/RCCAR.22000022
  22. Eichstaedt CA, Belge C, Chung WK, Graf S, Grunig E, Montani D, et al. Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH. Eur Respir J. 2023;61(2). doi:10.1183/13993003.01471-2022 DOI: https://doi.org/10.1183/13993003.01471-2022
  23. Canadian Agency for Drugs and Technologies in Health. Drugs for Pulmonary Arterial Hypertension: Comparative Efficacy, Safety, and Cost-Effectiveness. Recommendations Report. Ottawa (ON): CADTH Therapeutic Reviews; 2018.
  24. Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. Chest. 2019;155(3):565-86. doi:10.1016/j.chest.2018.11.030 DOI: https://doi.org/10.1016/j.chest.2018.11.030
  25. Varela DL, Teleb M, El-Mallah W. Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review. Open Heart. 2018;5(1):e000744. doi:10.1136/openhrt-2017-000744 DOI: https://doi.org/10.1136/openhrt-2017-000744
  26. Villanueva DLE, Agustin RD, Llanes EJ. Pre-Operative Sildenafil for Patients With Pulmonary Hypertension Undergoing Mitral Valve Surgery: A Systematic Review and Meta-Analysis. Cardiol Res. 2019;10(6):369-77. doi:10.14740/cr962 DOI: https://doi.org/10.14740/cr962
  27. Ullah W, Minalyan A, Saleem S, Nadeem N, Abdullah HM, Abdalla A, et al. Comparative accuracy of non-invasive imaging versus right heart catheterization for the diagnosis of pulmonary hypertension: A systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2020;29:100568. doi:10.1016/j.ijcha.2020.100568 DOI: https://doi.org/10.1016/j.ijcha.2020.100568
  28. Schlueter M, Beaudet A, Davies E, Gurung B, Karabis A. Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal. BMC Pulm Med. 2020;20(1):202. doi:10.1186/s12890-020-01241-4 DOI: https://doi.org/10.1186/s12890-020-01241-4
  29. Arvanitaki A, Giannakoulas G, Triantafyllidou E, Karvounis H, Garyfallos A, Kitas G, et al. Nailfold videocapillaroscopy: a novel possible surrogate marker for the evaluation of peripheral microangiopathy in pulmonary arterial hypertension. Scand J Rheumatol. 2021;50(2):85-94. doi:10.1080/03009742.2020.1786854 DOI: https://doi.org/10.1080/03009742.2020.1786854
  30. Alabed S, Shahin Y, Garg P, Alandejani F, Johns CS, Lewis RA, et al. Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. JACC Cardiovasc Imaging. 2021;14(5):931-42. doi:10.1016/j.jcmg.2020.08.013 DOI: https://doi.org/10.1016/j.jcmg.2020.08.013
  31. Price LC, Martinez G, Brame A, Pickworth T, Samaranayake C, Alexander D, et al. Perioperative management of patients with pulmonary hypertension undergoing non-cardiothoracic, non-obstetric surgery: a systematic review and expert consensus statement. Br J Anaesth. 2021;126(4):774-90. doi:10.1016/j.bja.2021.01.005 DOI: https://doi.org/10.1016/j.bja.2021.01.005
  32. Tan Z, Wu PY, Zhu TT, Su W, Fang ZF. Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials. Pulm Pharmacol Ther. 2022;76:102144. doi:10.1016/j.pupt.2022.102144 DOI: https://doi.org/10.1016/j.pupt.2022.102144
  33. Lim MWS, Setjiadi D, Dobbin SJH, Lang NN, Delles C, Connelly PJ. Nailfold video-capillaroscopy in the study of cardiovascular disease: a systematic review. Blood Press Monit. 2023;28(1):24-32. doi:10.1097/MBP.0000000000000624 DOI: https://doi.org/10.1097/MBP.0000000000000624
  34. Lokhorst C, van der Werf S, Berger RMF, DoUWes JM. Risk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review. Front Cardiovasc Med. 2022;9:1035453. doi:10.3389/fcvm.2022.1035453 DOI: https://doi.org/10.3389/fcvm.2022.1035453
  35. Balakrishnan B, Owens B, Hayes R, Wen S. A Systematic Review of Echocardiographic Parameters for the Screening of Pulmonary Hypertension: What Are the Odds? Cureus. 2022;14(12):e32185. doi:10.7759/cureus.32185 DOI: https://doi.org/10.7759/cureus.32185
  36. Scagliola R, Brunelli C, Balbi M. Pulmonary Arterial Hypertension in the Elderly: Peculiar Features and Challenges for a Proper Phenotyping Approach. Journal of Cardiovascular Development and Disease. 2023;10(9):401. DOI: https://doi.org/10.3390/jcdd10090401
  37. Liu YY, Qu YY, Wang S, Luo CJ, Qiu HL, Li HT, et al. Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis. Front Pharmacol. 2023;14:1052546. doi:10.3389/fphar.2023.1052546 DOI: https://doi.org/10.3389/fphar.2023.1052546
  38. Atsumi T, Bae SC, Gu H, Huang WN, Li M, Nikpour M, et al. Risk Factors for Pulmonary Arterial Hypertension in Patients With Systemic Lupus Erythematosus: A Systematic Review and Expert Consensus. ACR Open Rheumatol. 2023;5(12):663-76. doi:10.1002/acr2.11611 DOI: https://doi.org/10.1002/acr2.11611
  39. Smith V, Vanhaecke A, Vandecasteele E, Guerra M, Paolino S, Melsens K, et al. Nailfold Videocapillaroscopy in Systemic Sclerosis-related Pulmonary Arterial Hypertension: A Systematic Literature Review. J Rheumatol. 2020;47(6):888-95. doi:10.3899/jrheum.190296 DOI: https://doi.org/10.3899/jrheum.190296
  40. McLaughlin VV, Channick R, De Marco T, Farber HW, Gaine S, Galie N, et al. Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. Chest. 2020;157(4):955-65. doi:10.1016/j.chest.2019.10.043 DOI: https://doi.org/10.1016/j.chest.2019.10.043
  41. Valverde AB, Soares JM, Viana KP, Gomes B, Soares C, Souza R. Pulmonary arterial hypertension in Latin America: epidemiological data from local studies. BMC Pulmonary Medicine. 2018;18(1):106. doi: 10.1186/s12890-018-0667-8 DOI: https://doi.org/10.1186/s12890-018-0667-8
  42. Farmakis IT, Vrana E, Mouratoglou SA, Zafeiropoulos S, Zanos S, Giannakoulas G. Haemodynamic effects of initial combination therapy in pulmonary arterial hypertension: a systematic review and meta-analysis. ERJ Open Res. 2022;8(4):00313-2022. doi:10.1183/23120541.00313-2022 DOI: https://doi.org/10.1183/23120541.00313-2022
  43. Wronski SL, Mordin M, Kelley K, Anguiano RH, Classi P, Shen E, et al. The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension. Lung. 2020;198(1):65-86. doi:10.1007/s00408-019-00289-2 DOI: https://doi.org/10.1007/s00408-019-00289-2
  44. Madigan S, Proudman S, Schembri D, Davies H, Adams R. Use of exercise tests in screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review. J Scleroderma Relat Disord. 2024 Feb;9(1):50-58. doi: 10.1177/23971983231199148. DOI: https://doi.org/10.1177/23971983231199148
  45. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. Gac Sanit. 2018;32(2):167 e1- e10. doi:10.1016/j.gaceta.2017.03.008 DOI: https://doi.org/10.1016/j.gaceta.2017.03.008
  46. Mendoza C, Kraemer P, Herrera P, Burdiles P, Sepúlveda D, Núñez E, et al. Cómo interpretar guías de práctica clínica elaboradas con metodología GRADE. Revista Médica de Chile. 2017;145(11):1463-70. DOI: https://doi.org/10.4067/s0034-98872017001101463
  47. Ogden SR, Culp WC, Jr., Villamaria FJ, Ball TR. Developing a Checklist: Consensus Via a Modified Delphi Technique. J Cardiothorac Vasc Anesth. 2016;30(4):855-8. doi:10.1053/j.jvca.2016.02.022 DOI: https://doi.org/10.1053/j.jvca.2016.02.022
  48. Goldet G, Howick J. Understanding GRADE: an introduction. J Evid Based Med. 2013;6(1):50-4. doi:10.1111/jebm.12018 DOI: https://doi.org/10.1111/jebm.12018
  49. Miranda PA, Guzmán Sáenz RC, Baños I, Alvarez Á. Epidemiología de la hipertensión pulmonar en Colombia. Revista Salud Uninorte. 2018;34(3):607-24. DOI: https://doi.org/10.14482/sun.34.3.614.4
  50. Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492. doi:10.1136/bmj.j5492 DOI: https://doi.org/10.1136/bmj.j5492
  51. Zhang ZQ, Zhu SK, Wang M, Wang XA, Tong XH, Wan JQ, et al. New progress in diagnosis and treatment of pulmonary arterial hypertension. J Cardiothorac Surg. 2022;17(1):216. doi:10.1186/s13019-022-01947-y DOI: https://doi.org/10.1186/s13019-022-01947-y
  52. Becerra-Muñoz VM, Gómez Sáenz JT, Escribano Subías P. The importance of data in Pulmonary Arterial Hypertension: from international registries to Machine Learning. Medicina Clinica. 2024. doi:10.1016/j.medcli.2023.12.010 DOI: https://doi.org/10.1016/j.medcle.2023.12.014
  53. Benavides-Luna HM. Fisiopatología de la hipertensión arterial pulmonar. Revista Colombiana de Cardiología. 2017;24:11-5. DOI: https://doi.org/10.1016/j.rccar.2017.07.001
  54. Villaquirán-Torres C. Evaluación diagnóstica en hipertensión arterial pulmonar. Revista Colombiana de Cardiología. 2017;24:20-7. DOI: https://doi.org/10.1016/j.rccar.2017.08.004
  55. Kovacs G, Avian A, Foris V, Tscherner M, Kqiku X, Douschan P, et al. Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension. PLoS One. 2016;11(12):e0168706. doi:10.1371/journal.pone.0168706 DOI: https://doi.org/10.1371/journal.pone.0168706
  56. Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2017;18(12):1301-10. doi:10.1093/ehjci/jex244 DOI: https://doi.org/10.1093/ehjci/jex244
  57. Dong TX, Zhu Q, Wang ST, Wang YH, Li GY, Kong FX, et al. Diagnostic and prognostic value of echocardiography in pulmonary hypertension: an umbrella review of systematic reviews and meta-analyses. BMC Pulm Med. 2023;23(1):253. doi:10.1186/s12890-023-02552-y DOI: https://doi.org/10.1186/s12890-023-02552-y
  58. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant. 2016;35(1):1-23. doi:10.1016/j.healun.2015.10.023 DOI: https://doi.org/10.1016/j.healun.2015.10.023
  59. Barbera J, Blanco I, Rubio J. Protocolos Nuevos retos en hipertensión pulmonar. Sociedad Española de Medicina Interna. 2019:1-10.
  60. Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012;142(6):1383-90. doi:10.1378/chest.11-2212 DOI: https://doi.org/10.1378/chest.11-2212
  61. Levine DJ. Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients. Am J Manag Care. 2021;27(3 Suppl):S35-S41. doi:10.37765/ajmc.2021.88609 DOI: https://doi.org/10.37765/ajmc.2021.88609
  62. Galie N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2019;53(1). doi:10.1183/13993003.02148-2018 DOI: https://doi.org/10.1183/13993003.02148-2018
  63. Riley JM, Fradin JJ, Russ DH, Warner ED, Brailovsky Y, Rajapreyar I. Post-Capillary Pulmonary Hypertension: Clinical Review. J Clin Med. 2024;13(2). doi:10.3390/jcm13020625 DOI: https://doi.org/10.3390/jcm13020625
  64. Morrell NW, Aldred MA, Chung WK, Elliott CG, Nichols WC, Soubrier F, et al. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J. 2019;53(1). doi:10.1183/13993003.01899-2018 DOI: https://doi.org/10.1183/13993003.01899-2018
  65. Cirino AL, Harris S, Lakdawala NK, Michels M, Olivotto I, Day SM, et al. Role of Genetic Testing in Inherited Cardiovascular Disease: A Review. JAMA Cardiol. 2017;2(10):1153-60. doi:10.1001/jamacardio.2017.2352 DOI: https://doi.org/10.1001/jamacardio.2017.2352
  66. Swietlik EM, Graf S, Morrell NW. The role of genomics and genetics in pulmonary arterial hypertension. Glob Cardiol Sci Pract. 2020;2020(1):e202013. doi:10.21542/gcsp.2020.13 DOI: https://doi.org/10.21542/gcsp.2020.13
  67. Welch CL, Aldred MA, Balachandar S, Dooijes D, Eichstaedt CA, Gräf S, et al. Defining the clinical validity of genes reported to cause pulmonary arterial hypertension. Genetics in Medicine. 2023;25(11):100925. doi:10.1016/j.gim.2023.100925 DOI: https://doi.org/10.1016/j.gim.2023.100925
  68. Graf S, Haimel M, Bleda M, Hadinnapola C, Southgate L, Li W, et al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun. 2018;9(1):1416. doi:10.1038/s41467-018-03672-4 DOI: https://doi.org/10.1038/s41467-018-03672-4
  69. Ministerio de Salud y Protección Social. Resolución 2275 de 2022 por la cual se establece la Clasifición Unica de Procedimientos en Salud CUPS. Bogotá D.C.: MSPS; 2022.
  70. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed). 2016;69(2):177. doi:10.1016/j.rec.2016.01.002 DOI: https://doi.org/10.1016/j.rec.2016.01.002
  71. Fox BD, Shimony A, Langleben D, Hirsch A, Rudski L, Schlesinger R, et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J. 2013;42(4):1083-91. doi:10.1183/09031936.00091212 DOI: https://doi.org/10.1183/09031936.00091212
  72. Khangoora V, Bernstein EJ, King CS, Shlobin OA. Connective tissue disease-associated pulmonary hypertension: A comprehensive review. Pulm Circ. 2023;13(4):e12276. doi:10.1002/pul2.12276 DOI: https://doi.org/10.1002/pul2.12276
  73. Erdogan M, Kilickiran Avci B, Ebren C, Ersoy Y, Ongen Z, Ongen G, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis in the era of new pulmonary arterial hypertension definitions. Clin Exp Rheumatol. 2024 Aug;42(8):1590-1597. doi:10.55563/clinexprheumatol/gzo4r2 DOI: https://doi.org/10.55563/clinexprheumatol/gzo4r2
  74. Hao Y, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C, et al. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther. 2015;17(1):7. doi:10.1186/s13075-015-0517-5 DOI: https://doi.org/10.1186/s13075-015-0517-5
  75. Coghlan JG, Denton CP, Grunig E, Bonderman D, Distler O, Khanna D, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340-9. doi:10.1136/annrheumdis-2013-203301 DOI: https://doi.org/10.1136/annrheumdis-2013-203301
  76. Distler O, Bonderman D, Coghlan JG, Denton CP, Grunig E, Khanna D, et al. Performance of DETECT Pulmonary Arterial Hypertension Algorithm According to the Hemodynamic Definition of Pulmonary Arterial Hypertension in the 2022. European Society of Cardiology and the European Respiratory Society Guidelines. Arthritis Rheumatol. 2024;76(5):777-82. doi:10.1002/art.42791 DOI: https://doi.org/10.1002/art.42791
  77. Guillen-Del Castillo A, Callejas-Moraga EL, Garcia G, Rodriguez-Palomares JF, Roman A, Berastegui C, et al. High sensitivity and negative predictive value of the DETECT algorithm for an early diagnosis of pulmonary arterial hypertension in systemic sclerosis: application in a single center. Arthritis Res Ther. 2017;19(1):135. doi:10.1186/s13075-017-1327-8 DOI: https://doi.org/10.1186/s13075-017-1327-8
  78. Bruni C, De Luca G, Lazzaroni MG, Zanatta E, Lepri G, Airo P, et al. Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review. Eur J Intern Med. 2020;78:17-25. doi:10.1016/j.ejim.2020.05.042 DOI: https://doi.org/10.1016/j.ejim.2020.05.042
  79. Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70(3):476-81. doi:10.1136/ard.2010.136929 DOI: https://doi.org/10.1136/ard.2010.136929
  80. Lemmers JM, van Caam AP, Kersten B, van den Ende CH, Knaapen H, van Dijk AP, et al. Nailfold capillaroscopy and candidate-biomarker levels in systemic sclerosis-associated pulmonary hypertension: A cross-sectional study. J Scleroderma Relat Disord. 2023;8(3):221-30. doi:10.1177/23971983231175213 DOI: https://doi.org/10.1177/23971983231175213
  81. Sanchez-Aguilera Sanchez-Paulete P, Lazaro Salvador M, Berenguel Senen A, Mendez Perles C, Rodriguez Padial L. Role of cardiopulmonary exercise test in early diagnosis of pulmonary hypertension in scleroderma patients. Med Clin (Barc). 2023;160(7):283-8. doi:10.1016/j.medcli.2022.07.012 DOI: https://doi.org/10.1016/j.medcle.2022.07.027
  82. Beshay S, Sahay S, Humbert M. Evaluation and management of pulmonary arterial hypertension. Respir Med. 2020;171:106099. doi:10.1016/j.rmed.2020.106099 DOI: https://doi.org/10.1016/j.rmed.2020.106099
  83. Sherman AE, Saggar R. Cardiopulmonary Exercise Testing in Pulmonary Arterial Hypertension. Heart Fail Clin. 2023;19(1):35-43. doi:10.1016/j.hfc.2022.08.015 DOI: https://doi.org/10.1016/j.hfc.2022.08.015
  84. Babu AS, Myers J, Arena R, Maiya AG, Padmakumar R. Evaluating exercise capacity in patients with pulmonary arterial hypertension. Expert Rev Cardiovasc Ther. 2013;11(6):729-37. doi:10.1586/erc.13.33 DOI: https://doi.org/10.1586/erc.13.33
  85. Bluro IM, Barbagelata L, Coronel ML, Melatini L, Svetliza G, Vulcano N, et al. Cardiopulmonary Exercise Testing Contributes to Accurate Risk Assessment in Patients with Low-risk Pulmonary Hypertension. Revista Argentina de Cardiologia. 2023;91(2):130-4. doi:10.7775/rac.v91.i2.20613 DOI: https://doi.org/10.7775/rac.v91.i2.20613
  86. Pagel R, Wulff K. On the mechanism of Phausis splendidula bioluminescence. Photochem Photobiol. 1980;32(1):111-2. doi:10.1111/j.1751-1097.1980.tb03996.x DOI: https://doi.org/10.1111/j.1751-1097.1980.tb03996.x
  87. Kao CC, Wedes SH, Hsu JW, Bohren KM, Comhair SA, Jahoor F, et al. Arginine metabolic endotypes in pulmonary arterial hypertension. Pulm Circ. 2015;5(1):124-34. doi:10.1086/679720 DOI: https://doi.org/10.1086/679720
  88. Welch CL, Aldred MA, Balachandar S, Dooijes D, Eichstaedt CA, Graf S, et al. Defining the clinical validity of genes reported to cause pulmonary arterial hypertension. Genet Med. 2023;25(11):100925. doi:10.1016/j.gim.2023.100925 DOI: https://doi.org/10.1016/j.gim.2023.100925
  89. Navas P, Tenorio J, Quezada CA, Barrios E, Gordo G, Arias P, et al. Molecular Analysis of BMPR2, TBX4, and KCNK3 and genotype-phenotype correlations in spanish patients and families with idiopathic and hereditary pulmonary arterial hypertension. Rev Esp Cardiol (Engl Ed). 2016;69(11):1011-9. doi:10.1016/j.rec.2016.03.029 DOI: https://doi.org/10.1016/j.rec.2016.03.029
  90. Vraka A, Diamanti E, Kularatne M, Yerly P, Lador F, Aubert JD, et al. Risk Stratification in Pulmonary Arterial Hypertension, Update and Perspectives. J Clin Med. 2023;12(13):4349. doi:10.3390/jcm12134349 DOI: https://doi.org/10.3390/jcm12134349
  91. Diez M, Caneva J, Diez A, Perna ER, Aimone D, Bosio M, et al. Risk stratification, prognosis, and survival in a pulmonary arterial hypertension cohort in Latin America. A multicenter study. Respir Med Res. 2023;83:100945. doi:10.1016/j.resmer.2022.100945 DOI: https://doi.org/10.1016/j.resmer.2022.100945
  92. Kanwar M, Raina A, Lohmueller L, Kraisangka J, Benza R. The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension. Curr Hypertens Rep. 2019;21(6):45. doi:10.1007/s11906-019-0950-y DOI: https://doi.org/10.1007/s11906-019-0950-y
  93. Lu D, Cheng CY, Zhu XJ, Li JY, Zhu YJ, Zhou YP, et al. Heart Rate Response Predicts 6-Minutes Walking Distance in Pulmonary Arterial Hypertension. Am J Cardiol. 2023;204:207-14. doi:10.1016/j.amjcard.2023.07.056 DOI: https://doi.org/10.1016/j.amjcard.2023.07.056
  94. Hendriks PM, van de Groep LD, Veen KM, van Thor MCJ, Meertens S, Boersma E, et al. Prognostic value of brain natriuretic peptides in patients with pulmonary arterial hypertension: A systematic review and meta-analysis. Am Heart J. 2022;250:34-44. doi:10.1016/j.ahj.2022.05.006 DOI: https://doi.org/10.1016/j.ahj.2022.05.006
  95. Rorth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS, et al. Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction. Circ Heart Fail. 2020;13(2):e006541. doi:10.1161/CIRCHEARTFAILURE.119.006541 DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.119.006541
  96. Min J, Badesch D, Chakinala M, Elwing J, Frantz R, Horn E, et al. Prediction of health-related quality of life and hospitalization in pulmonary arterial hypertension: The Pulmonary hypertension association registry. Am J Respir Crit Care Med. 2021;203(6):761-4. doi:10.1164/rccm.202010-3967LE DOI: https://doi.org/10.1164/rccm.202010-3967LE
  97. Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175-81. doi:10.1093/eurheartj/ehx257 DOI: https://doi.org/10.1093/eurheartj/ehx257
  98. Benza RL, Kanwar MK, Raina A, Scott JV, Zhao CL, Selej M, et al. Development and validation of an abridged version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in patients with pulmonary arterial hypertension. Chest. 2021;159(1):337-46. doi:10.1016/j.chest.2020.08.2069 DOI: https://doi.org/10.1016/j.chest.2020.08.2069
  99. Gregorietti V. Hipertensión Pulmonar: estratificación de riesgo. Impacto de su reducción en el pronóstico. Revista de la Federación Argentina de Cardiología. 2019;48:5-9.
  100. Cruz-Utrilla A, Gallego-Zazo N, Pérez-Olivares C, Hernández-González I, Bedate P, Meñaca AM, et al. Utilidad de la genética en la reclasificación y la mejoría en la estratificación pronóstica en la hipertensión arterial pulmonar. Revista Española de Cardiología. 2023;76(6):460-7. DOI: https://doi.org/10.1016/j.recesp.2022.11.004
  101. Sahay S, Bhatt J, Beshay S, Guha A, Nguyen DT, Graviss EA, et al. E-REVEAL Lite 2.0 scoring for early prediction of disease progression in pulmonary arterial hypertension. Pulm Circ. 2022;12(1):e12026. doi:10.1002/pul2.12026 DOI: https://doi.org/10.1002/pul2.12026
  102. Anderson JJ, Lau EM, Lavender M, Benza R, Celermajer DS, Collins N, et al. Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand pulmonary hypertension registry cohort. Chest. 2020;157(1):162-72. doi:10.1016/j.chest.2019.08.2203 DOI: https://doi.org/10.1016/j.chest.2019.08.2203
  103. Zelniker TA, Huscher D, Vonk-Noordegraaf A, Ewert R, Lange TJ, Klose H, et al. The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. Clin Res Cardiol. 2018;107(6):460-70. doi:10.1007/s00392-018-1207-5 DOI: https://doi.org/10.1007/s00392-018-1207-5
  104. Deng X, Jin B, Li S, Li Y, Zhou H, Wu Y, et al. Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study. Clin Respir J. 2019;13(11):693-9. doi:10.1111/crj.13076 DOI: https://doi.org/10.1111/crj.13076
  105. Yogeswaran A, Richter MJ, Sommer N, Ghofrani HA, Seeger W, Tello K, et al. Advanced risk stratification of intermediate risk group in pulmonary arterial hypertension. Pulm Circ. 2020;10(4):2045894020961739. doi:10.1177/2045894020961739 DOI: https://doi.org/10.1177/2045894020961739
  106. Mora Cuesta VM, Martinez Menaca A, Iturbe Fernandez D, Tello Mena S, Alonso Lecue P, Fernandez Marquez D, et al. Lack of concordance between the different exercise test measures used in the risk stratification of patients with pulmonary arterial hypertension. Pulm Circ. 2022;12(4):e12149. doi:10.1002/pul2.12149 DOI: https://doi.org/10.1002/pul2.12149
  107. Fernandes CJ, Calderaro D, Assad APL, Salibe-Filho W, Kato-Morinaga LT, Hoette S, et al. Update on the Treatment of Pulmonary Arterial Hypertension. Arq Bras Cardiol. 2021;117(4):750-64. doi:10.36660/abc.20200702 DOI: https://doi.org/10.36660/abc.20200702
  108. Barbera JA, Roman A, Gomez-Sanchez MA, Blanco I, Otero R, Lopez-Reyes R, et al. Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations. Arch Bronconeumol (Engl Ed). 2018;54(4):205-15. doi:10.1016/j.arbres.2017.11.014 DOI: https://doi.org/10.1016/j.arbr.2017.11.017
  109. Grunig E, MacKenzie A, Peacock AJ, Eichstaedt CA, Benjamin N, Nechwatal R, et al. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. Eur Heart J. 2021;42(23):2284-95. doi:10.1093/eurheartj/ehaa696 DOI: https://doi.org/10.1093/eurheartj/ehaa696
  110. Stickel S, Gin-Sing W, Wagenaar M, Gibbs JSR. The practical management of fluid retention in adults with right heart failure due to pulmonary arterial hypertension. Eur Heart J Suppl. 2019;21(Suppl K):K46-K53. doi:10.1093/eurheartj/suz207 DOI: https://doi.org/10.1093/eurheartj/suz207
  111. Adir Y, Humbert M, Chaouat A. Sleep-related breathing disorders and pulmonary hypertension. Eur Respir J. 2021;57(1). doi:10.1183/13993003.02258-2020 DOI: https://doi.org/10.1183/13993003.02258-2020
  112. Kingman M, Hinzmann B, Sweet O, Vachiery JL. Living with pulmonary hypertension: unique insights from an international ethnographic study. BMJ Open. 2014;4(5):e004735. doi:10.1136/bmjopen-2013-004735 DOI: https://doi.org/10.1136/bmjopen-2013-004735
  113. Caojin Z, Yigao H, Tao H, Wenhui H, Chunli X, Xinsheng H. Comparison of acute hemodynamic effects of aerosolized iloprost and inhaled nitric oxide in adult congenital heart disease with severe pulmonary arterial hypertension. Intern Med. 2012;51(20):2857-62. doi:10.2169/internalmedicine.51.7927 DOI: https://doi.org/10.2169/internalmedicine.51.7927
  114. Opitz CF, Wensel R, Bettmann M, Schaffarczyk R, Linscheid M, Hetzer R, et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J. 2003;24(4):356-65. doi:10.1016/s0195-668x(02)00302-0 DOI: https://doi.org/10.1016/S0195-668X(02)00302-0
  115. Kiani A, Omidvar R, Naderi N, Taghavi S, Mirtajaddini M. The Long-Term response to treatment with calcium channel blockers in patients with idiopathic pulmonary arterial hypertension. J Tehran Heart Cent. 2023;18(1):62-7. doi:10.18502/jthc.v18i1.12583 DOI: https://doi.org/10.18502/jthc.v18i1.12583
  116. Kularatne M, Gerges C, Jevnikar M, Humbert M, Montani D. Updated Clinical Classification and Hemodynamic Definitions of Pulmonary Hypertension and Its Clinical Implications. J Cardiovasc Dev Dis. 2024;11(3). doi:10.3390/jcdd11030078 DOI: https://doi.org/10.3390/jcdd11030078
  117. Pintado B, Tenes A. Protocolo terapéutico de la hipertensión pulmonar sin cardiopatía izquierda. Medicine-Programa de Formación Médica Continuada Acreditado. 2022;13(68):4015-20. DOI: https://doi.org/10.1016/j.med.2022.11.014
  118. Chin KM, Sitbon O, Doelberg M, Feldman J, Gibbs JSR, Grunig E, et al. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2021;78(14):1393-403. doi:10.1016/j.jacc.2021.07.057 DOI: https://doi.org/10.1016/j.jacc.2021.07.057
  119. Gall H, Vachiery JL, Tanabe N, Halank M, Orozco-Levi M, Mielniczuk L, et al. Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH. Lung. 2018;196(3):305-12. doi:10.1007/s00408-018-0100-3 DOI: https://doi.org/10.1007/s00408-018-0100-3
  120. Benza RL, Corris PA, Klinger JR, Langleben D, Naeije R, Simonneau G, et al. Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. Int J Cardiol. 2020;317:188-92. doi:10.1016/j.ijcard.2020.05.044 DOI: https://doi.org/10.1016/j.ijcard.2020.05.044
  121. Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JSR, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2021;9(6):573-84. doi:10.1016/S2213-2600(20)30532-4 DOI: https://doi.org/10.1016/S2213-2600(20)30532-4
  122. Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24(3):353-9. doi:10.1183/09031936.04.00028404 DOI: https://doi.org/10.1183/09031936.04.00028404
  123. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174(11):1257-63. doi:10.1164/rccm.200603-358OC DOI: https://doi.org/10.1164/rccm.200603-358OC
  124. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-22. doi:10.1016/j.jacc.2010.01.027 DOI: https://doi.org/10.1016/j.jacc.2010.01.027
  125. Hoeper MM, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;28(4):691-4. doi:10.1183/09031936.06.00057906 DOI: https://doi.org/10.1183/09031936.06.00057906
  126. Rosenkranz S, Channick R, Chin KM, Jenner B, Gaine S, Galie N, et al. The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study. Eur J Heart Fail. 2022;24(1):205-14. doi:10.1002/ejhf.2369 DOI: https://doi.org/10.1002/ejhf.2369
  127. Genecand L, Wacker J, Beghetti M, Lador F. Selexipag for the treatment of pulmonary arterial hypertension. Expert Rev Respir Med. 2021;15(5):583-95. doi:10.1080/17476348.2021.1866990 DOI: https://doi.org/10.1080/17476348.2021.1866990
  128. Panagiotidou E, Boutou A, Pitsiou G. An evaluation of selexipag for the treatment of pulmonary hypertension. Expert Opin Pharmacother. 2021;22(1):29-36. doi:10.1080/14656566.2020.1812579 DOI: https://doi.org/10.1080/14656566.2020.1812579
  129. Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M, et al. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Circulation. 2018;137(7):693-704. doi:10.1161/CIRCULATIONAHA.117.029254 DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.029254
  130. Aguilar Aguilar LF. Estimación de la presión arterial pulmonar mediante diferentes métodos ecocardiográficos y su correlación con medición invasiva. Monterrey: UDEM; 2020.
  131. Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, et al. Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circulation. 2016;133(13):1240-8. doi:10.1161/CIRCULATIONAHA.115.020207 DOI: https://doi.org/10.1161/CIRCULATIONAHA.115.020207
  132. Lema LR. Highlights 6° Simposio Mundial sobre Hipertensión Pulmonar-Niza 2018: RECOPILAR: Registro Colaborativo Argentino de Hipertensión Pulmonar. Revista de la Federación Argentina de Cardiología. 2019;48:10-2.
  133. Xanthouli P, Jordan S, Milde N, Marra A, Blank N, Egenlauf B, et al. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. Ann Rheum Dis. 2020;79(3):370-8. doi:10.1136/annrheumdis-2019-216476 DOI: https://doi.org/10.1136/annrheumdis-2019-216476
  134. Spilimbergo FB, Pirath Rodrigues R, Credidio Dias-Pinto M, Blanco DC, Barbieri GM, Andrade-Lima M, et al. Risk assessment validation in patients with pulmonary arterial hypertension: Data from a Southern Brazil registry (RESPHIRAR Study). Pulm Circ. 2023;13(1):e12193. doi:10.1002/pul2.12193 DOI: https://doi.org/10.1002/pul2.12193
  135. Doyle-Cox C, Nicholson G, Stewart T, Gin-Sing W. Current organization of specialist pulmonary hypertension clinics: results of an international survey. Pulm Circ. 2019;9(2):2045894019855611. doi:10.1177/2045894019855611 DOI: https://doi.org/10.1177/2045894019855611
  136. Deano RC, Glassner-Kolmin C, Rubenfire M, Frost A, Visovatti S, McLaughlin VV, et al. Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study. JAMA Intern Med. 2013;173(10):887-93. doi:10.1001/jamainternmed.2013.319 DOI: https://doi.org/10.1001/jamainternmed.2013.319
  137. Ministerio de Salud y Protección Social. Plan Nacional de Salud Rural. Bogotá D.C.: MSPS; 2018.
  138. American Thoracic Society. International Conference B56 Let's get physical: exercise and biomechanics of PAH. American Journal of Respiratory and Critical Care Medicine 2019(199). Available from: https://www.atsjournals.org/doi/book/10.1164/ajrccm-conference.2019.B56.
  139. Schoenberg N, Ruopp N, Wilson K, Farber H. Volume Challenge in Occult Pulmonary Venous Hypertension: A Systematic Review of the Literature. B56 Let's get physical: exercise and biomechanics of PAH. 2019:A3670-A. DOI: https://doi.org/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3670
  140. Pezzuto B, Agostoni P. The Current Role of Cardiopulmonary Exercise Test in the Diagnosis and Management of Pulmonary Hypertension. J Clin Med. 2023;12(17). doi:10.3390/jcm12175465 DOI: https://doi.org/10.3390/jcm12175465
Tutoriales

Autores:

¿Cómo enviar un artículo?

Par evaluador:

¿Cómo evaluar un artículo?

Información

Historia de la revista

Palabras clave

Directorios e indexadores

 

Patrocinadores

 Nos apoyan + Info Aquí 

 
Perfil de Google Scholar

Más leídos en los últimos 30 días

Número actual

Código QR

Sistema OJS 3.4.0.7 - Metabiblioteca |